US TOO! Surveys Prostate Ca Patients
NEW YORK-Although 90% of prostate cancer patients in a Harris poll cited delay of disease progression as a key benefit they seek from a therapy, only one third of physicians said they would be very likely to recommend complete hormonal therapy (CHT) (an oral antian-drogen drug plus castration therapy) for all of their stage D patients. Nearly all physicians said they discuss CHT with patients, but more than 50% of patients said it had not been presented as a treatment option. The poll was sponsored by the advocacy group US TOO! and funded by Schering Oncology/Biotech.
NEW YORK-Although 90% of prostate cancer patients in a Harrispoll cited delay of disease progression as a key benefit theyseek from a therapy, only one third of physicians said they wouldbe very likely to recommend complete hormonal therapy (CHT) (anoral antian-drogen drug plus castration therapy) for all of theirstage D patients. Nearly all physicians said they discuss CHTwith patients, but more than 50% of patients said it had not beenpresented as a treatment option. The poll was sponsored by theadvocacy group US TOO! and funded by Schering Oncology/Biotech.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F9addaac21d809a7b642a567b0a704cbb15d87ac5-2966x1684.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.")
